Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
KLAC$129.76-19.89(-13.29%)KLA Declares Regular Cash Dividend4:30:14 PM ETKO$95.75-0.13(-0.14%)DRIVX Moves Toward Final Presale Stage, Unveils Fleet Expansion and Transparent Vesting Strategy4:19:08 PM ETCRWD$217.00-23.98(-9.95%)Why CrowdStrike and cybersecurity stocks got crunched in Thursday's rout4:12:00 PM ETLRCX$192.19-29.09(-13.15%)Lam Research Corporation Announces $25 Billion Share Repurchase Authorization and Declares Quarterly Dividend4:05:00 PM ETSKHY$124.76-18.32(-12.80%)Why SK Hynix Plunged Today4:01:39 PM ETNVDA$182.13-18.16(-9.07%)Is Nvidia Still a Millionaire-Maker Stock?3:51:00 PM ETTSLA$342.08-43.10(-11.19%)SpaceX and Tesla Stock Plunges Have Wiped About $450 Billion in Value Since the Midterms. Is It Time to Buy?3:43:35 PM ETGOOGL$280.75-8.28(-2.86%)Google plans $17 billion Wyoming data center amid rising threats of curbs3:43:13 PM ETNOW$101.20-7.71(-7.08%)Arista Networks vs. ServiceNow: Which Technology Stock Is a Better Buy for 2027?3:43:02 PM ETGOOGL$280.75-8.28(-2.86%)BREAKINGVIEWS-Global muscle will sift puny data center providers3:30:09 PM ETAMD$408.79-79.90(-16.35%)Is AMD Stock a Buy as AI Revenue Soars?3:19:00 PM ETGEV$769.00-63.51(-7.63%)GE Vernova vs. NextEra Energy: Which Industrials Stock Is a Better Buy for 2027?3:17:11 PM ETBRK-A$857,487.54-9,063.79(-1.05%)Berkshire Hathaway Reports Nov. 7 With Its Stock at a Record. Its Cash Pile Is the Number to Watch.3:17:02 PM ETC$118.48+0.68(+0.58%)UPDATE 10-Brent crude jumps, settles up over $3 after tanker attacks3:15:37 PM ETCLX$99.50+0.30(+0.30%)Global Surface Disinfectant Market to Hit US$ 7.5 Bn by 2031, Registering at 7.4% CAGR: Wissen Research3:14:00 PM ETTM$215.73+16.37(+8.21%)ERI’s John Shegerian Describes the Current State of Rare Earth Mineral Recovery at World Remanufacturing Summit in Tokyo3:09:00 PM ETMRVL$134.70-25.21(-15.77%)Marvell Just Dropped 49% in a Month: Is MRVL Stock Hopeless or Ready for a Rebound?3:03:21 PM ETSPCX$123.59-12.24(-9.01%)Bull v. Bear: SPCX Faces Uncertainty as Midterm Results Pressure TSLA Merger3:00:38 PM ETINTC$52.26-6.02(-10.33%)Intel Shares Rise 6% To Intraday High After Key Trading Signal3:00:27 PM ETAMD$408.79-79.90(-16.35%)Advanced Micro Devices vs. Taiwan Semiconductor Manufacturing: The AI Sell-Off Is Exposing a Critical Difference Investors Shouldn't Ignore for 20273:00:02 PM ETHSY$177.43+2.93(+1.68%)Hershey vs. Coca-Cola: Which Consumer Goods Stock Is a Better Buy for 2027?2:51:29 PM ETCRWD$217.00-23.98(-9.95%)CrowdStrike Stock Plummets on AI Regulation Fears2:50:42 PM ETMETA$602.76-26.91(-4.27%)Meta says US users can now video chat with their Muse AI avatar2:48:28 PM ETWFC$84.74-2.72(-3.11%)UNCF Empower Me Tour Continues in Milwaukee, WI, on Nov. 10th with College Readiness Conference, Offering Scholarships and On-Site College Admissions2:43:35 PM ET

GYRE · NASDAQ

Gyre Therapeutics, Inc.

$4.00 -0.44 (-9.91%)

Company overview

Gyre Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. Its product offerings include ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis, along with additional Phase 3 studies for dermatomyositis, systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved in developing F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 studies for chronic hepatitis B liver fibrosis and Phase 1 studies for liver fibrosis associated with nonalcoholic steatohepatitis.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$424M
Employees
579
Headquarters
San Diego, CA
Website
gyretx.com
CEO
Ping Zhang
Listed
April 12, 2006
P/E
-54.13
Dividend yield
6.42%

Company financials

Revenue
$117M
Gross profit
$111M
Operating income
-$139,000
EBITDA
$2.6M
Net income
-$6.3M
EPS
-$0.07
Total assets
$162M
Total debt
$823,000
Gross margin
95.09%
Net margin
-5.37%
Earnings yield
-1.85%

Revenue segmentation

By product (FY 2024)
By region (FY 2024)

No geographic segmentation.

Showing FY 2024

Price chart

4.115.146.187.218.24
GYRE 1D NASDAQ O4.57H4.65L4.33C4.440.00 (0.00%)Vol256.45K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
GYREGyre Therapeutics, Inc. Press release Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates GlobeNewswire
GYREGyre Therapeutics, Inc. Stock news Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates GlobeNewswire
GYREGyre Therapeutics, Inc. Press release Gyre Therapeutics to Participate in Upcoming September Investor Conferences GlobeNewswire
GYREGyre Therapeutics, Inc. Stock news Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates Zacks Investment Research
GYREGyre Therapeutics, Inc. Press release Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update GlobeNewswire
GYREGyre Therapeutics, Inc. Press release Gyre Therapeutics Appoints Three New Members to its Board of Directors GlobeNewswire
GYREGyre Therapeutics, Inc. Legal Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm Newsfile Corp
GYREGyre Therapeutics, Inc. Press release Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment GlobeNewswire
GYREGyre Therapeutics, Inc. Stock news Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates Zacks Investment Research
GYREGyre Therapeutics, Inc. Press release Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update GlobeNewswire
GYREGyre Therapeutics, Inc. Press release Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company GlobeNewswire
GYREGyre Therapeutics, Inc. Press release Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment GlobeNewswire
GYREGyre Therapeutics, Inc. Stock news Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates Zacks Investment Research
GYREGyre Therapeutics, Inc. Press release Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update GlobeNewswire
GYREGyre Therapeutics, Inc. Stock news Head-To-Head Contrast: Gyre Therapeutics (NASDAQ:GYRE) versus Tenax Therapeutics (NASDAQ:TENX) Defense World
GYREGyre Therapeutics, Inc. Press release Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline GlobeNewswire
GYREGyre Therapeutics, Inc. Stock news Analyzing Gyre Therapeutics (NASDAQ:GYRE) and ImmunityBio (NASDAQ:IBRX) Defense World
GYREGyre Therapeutics, Inc. Press release Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting GlobeNewswire
GYREGyre Therapeutics, Inc. Stock news Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates Zacks Investment Research
GYREGyre Therapeutics, Inc. Press release Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update GlobeNewswire
See more
FAQ

Questions about Gyre Therapeutics, Inc.

What does Gyre Therapeutics, Inc. do?
Gyre Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. Its product offerings include ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis, along with additional Phase 3 studies for dermatomyositis, systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved in developing F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 studies for chronic hepatitis B liver fibrosis and Phase 1 studies for liver fibrosis associated with nonalcoholic steatohepatitis.
What is GYRE's market cap?
Gyre Therapeutics, Inc. (GYRE) is a listed stock with a live quote. The latest market cap on this page is $424M.
Where is Gyre Therapeutics, Inc. headquartered?
Gyre Therapeutics, Inc. is headquartered in San Diego, CA.
How do I get GYRE news from the API?
Call GET /v1/news?tickers=GYRE. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does GYRE news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for GYRE, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the GYRE price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs